BCL-6 is essential for germinal center formation and thus for affinity maturation of immunoglobulin (Ig) genes by somatic mutations. The 5′-noncoding region of the BCL-6gene is even a target for the mutation machinery. Translocations of theBCL-6 gene to heterologous promoters and mutations of its 5′-noncoding regulatory region were reported to be potential mechanisms for deregulating BCL-6 expression and for playing a role in the genesis of non-Hodgkin lymphoma. In line with this hypothesis is the observation that B-cell lymphoma with somatic mutations, such as diffuse large B-cell lymphoma and follicular lymphoma, also carryBCL-6 mutations, some of which are recurrently detectable. Classic Hodgkin disease (cHD) is also derived from B cells with high loads of somatic mutations and thus a further candidate forBCL-6 mutations. To determine the presence and potential role of BCL-6 mutations in cHD, the 5′-noncodingBCL-6 proportion of single Hodgkin and Reed-Sternberg (HRS) cells from 6 cases of cHD and 6 cases of HD-derived cell lines was analyzed. All B-cell–derived HD cases and cell lines harboredBCL-6 mutations. In contrast, both T-cell–derived HD cases and cell lines were devoid of BCL-6 mutations. With only one exception, there were no lymphoma-specific recurrentBCL-6 mutations detected, and BCL-6 protein was absent from the HRS cells of most cases. In conclusion, (1) somaticBCL-6 mutations are restricted to cHD cases of B-cell origin, and (2) the BCL-6 mutations represent mostly irrelevant somatic base substitutions without consequences for BCL-6 protein expression and the pathogenesis of cHD.

The proto-oncogene BCL-6 is, with the exception of immunoglobulin (Ig) heavy and light chain genes, the only gene that is known to be significantly somatically mutated in the course of the germinal center (GC) reaction in B cells.1,2 These somatic mutations occur preferentially in the 5′-noncoding region of the BCL-6 gene.1 In addition, somatic hypermutations, as well as translocations, in theBCL-6 regulatory element are frequently found in B-cell lymphoma originating from GC or post-GC B cells.3-7 It is postulated that these alterations affecting the transcriptional activity of the BCL-6 gene are involved in the pathogenesis of several lymphoma entities.5-7 This holds especially true for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), which harbor, in addition to their highly mutatedIg genes, alterations in the 5′-noncoding region of theBCL-6 gene.3 5 

The tumor cells of classical Hodgkin disease (cHD), the Hodgkin and Reed-Sternberg (HRS) cells, are also derived from highly mutated GC or post-GC B cells in the vast majority of cases.8-10 Only a small proportion of cases originate from T cells, as shown by their rearranged TCR genes.11,12 It is therefore tempting to speculate that the 5′-noncoding region of theBCL-6 gene is mutated in HRS cells and, comparable to the situation described for FL and DLBCL, involved in the pathogenesis of cHD. However, BCL-6 is expressed in only a proportion of cHD cases,13 thereby raising the question of the significance of BCL-6 in HD. Furthermore, it is interesting to see whether there are differences in the mutational pattern ofBCL-6 in HRS cells of B- or T-cell genotype supporting the view of 2 different disease entities.

To clarify the mutational status of BCL-6 in cHD, we isolated single HRS cells from 6 patients and analyzed the 5′-noncoding region of the BCL-6 gene. Furthermore, nonneoplastic cells were isolated for comparison. Our data show that all patients with cHD with a B-cell genotype harbor mutated BCL-6 genes, whereas patients with cHD with T-cell genotype lack mutations. This lends further credit to the hypothesis that cHD of T- and B-cell genotype are biological distinct entities.

Tissue samples, cell lines, and immunostaining

From a series of cHD cases from the files of the Institute of Pathology, Berlin, Germany, we selected 6 cases. Two of these patients displayed a T-cell genotype, and 4 patients displayed a B-cell genotype. In addition, 6 HD-derived cell lines (L428, KMH2, L591, L1236, L540, and Holden) were included in this study.

DNA extraction

High molecular weight DNA was extracted from 5.0 × 106 cell line cells employing the QIAamp Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. DNA was dissolved in 100 μL distilled water, quantified photometrically, and used as a template for polymerase chain reaction (PCR).

Immunohistochemistry

Both lymph node biopsies and HD-derived cell lines were immunohistochemically analyzed by a panel of monoclonal antibodies against CD30 (Ber-H2), CD15 (C3D1), LMP-1 (CS1-4), CD20 (L26), BCL-6 (594), CD3 (UCHT1), CD8 (C8/144B) (all from Dako Diagnostics, Hamburg, Germany), and perforin (P1-8) (Kamiya Biomedical Company, Seattle, WA). Immunostaining was performed on frozen or formalin-fixed, paraffin-embedded sections employing the of alkaline phosphatase antialkaline phosphatase (APAAP) technique.14Paraffin-embedded sections were pretreated by pressure cooking as previously described.15 

Single cell isolation

Using a hydraulic micromanipulation device, CD30+HRS cells were isolated from immunostained frozen tissue sections from 6 patients with cHD.16 We pooled 2-7 single HRS cells to obtain higher PCR amplification rates. All cases were analyzed at least twice in completely independent cell isolation procedures and PCR assays. In cases with mutated BCL-6 5′-noncoding sequences in the HRS cells (reference sequence AF191831),5additional CD30 reactive cells were investigated to rule out individual polymorphism. Furthermore, buffers overlaying the tissue sections during the cell isolation process were used as negative controls.

PCR

Isolated cells were digested with 0.1 mg/mL proteinase K (Boehringer Mannheim, Mannheim, Germany) for 1 hour at 50°C and, after heat denaturation of the enzyme, subjected to a seminestedBCL-6 PCR. The PCR was carried with Taq buffer (PerkinElmer) supplemented with 1.5 mM magnesium dichloride (MgCl2), 0.8 mM dNTP (deoxynucleoside-5′-triphosphate), 50 ng of each primer, and 2 U Taq DNA polymerase (PerkinElmer). The first round of amplification was performed employing bcl6up (5′-ATG CTT TGG CTC CAA GTT-3′) and bcl6low (5′-CAC GAT ACT TCA TCT CAT C-3′). For re-amplification the bcl6low primer was replaced by a nested bcl6low2 primer (5′-CGG CTC GAA GGC AGG-3′). The PCR conditions were 96°C for 15 seconds, 62°C for 1 minute, and 72°C for 50 seconds for the initial 5 cycles. For the remaining 35 cycles the annealing conditions were reduced to 60°C for 30 seconds. The re-amplification was carried out under the same PCR conditions with the exception of 10 initial cycles of higher stringency instead of 5 cycles. Negative and positive controls for single cell analysis were performed under the same conditions, whereas 400 ng cell line DNA was amplified by only one round of PCR. Reaction mixtures were analyzed on 1.5% agarose gels and stained with ethidium bromide. Bands of appropriate size were excised from the gels and purified with the Qiaex-2 DNA isolation kit (Qiagen).

Cloning and sequencing of PCR products

Purified PCR products obtained from B-cell–derived HD cell lines were cloned (Topo cloning, Invitrogen, Westbrook, ME), and 10-20 randomly selected colonies were sequenced by fluorescence chain termination technique (Bigdye; ABI, Weiterstadt, Germany) on an automated sequencer (ABI 377A, ABI). The resulting sequences were compared to published data bank sequences (GenBank) and our own unpublished sequences.

Genotype and immunophenotype of the HRS cells

The genotype and expression profile of the 6 cHD cases used for the present study have been described elsewhere.12 In brief, the HRS cells of 4 cases harbored highly mutated rearrangedIgH genes, whereas the other 2 cases displayed HRS cells with clonal TCR rearrangements.12 16 Both cases with rearranged TCR genes displayed a strong expression of perforin in all tumor cells. One of the cases with a B-cell genotype (patient no. 5) was positive for the Epstein-Barr virus (EBV)–encoded LMP-1 protein (Table 1).

Table 1.

Genotype and immunophenotype of the Hodgkin and Reed-Sternberg cells

Patient no.Age, y/sexGenotypeCD30CD15CD20CD3CD8PerforinEBV LMP-1
56/M − − − − 
72/M − −/+ −/+ − 
NA − −/+ − − − 
34/M − − − − 
35/M − − − − 
31/F − +/− − − − 
Patient no.Age, y/sexGenotypeCD30CD15CD20CD3CD8PerforinEBV LMP-1
56/M − − − − 
72/M − −/+ −/+ − 
NA − −/+ − − − 
34/M − − − − 
35/M − − − − 
31/F − +/− − − − 

EBV indicates Epstein-Barr virus; T, T cell; B, B cell; NA, not available; +, positive; −, negative; +/−, more than 50% positive; −/+, more than 50% negative.

The expression of BCL-6 was heterogeneous among the cases and cell lines investigated. Two cHD cases (one case with TCRrearrangement and one with IgH rearrangement) disclosed a BCL-6 expression of virtually all HRS cells, whereas BCL-6 was completely absent in the HRS cells of 2 further cases (both withIgH rearrangement). In the remaining 2 cases, scattered HRS cells were BCL-6+. Imunostaining of HD-derived cell lines for BCL-6 revealed single BCL-6+ cells in cell lines L1236, L428, KMH2, and Holden. Up to 10% of the cells were positive only in cell lines L540 and L591 (Table 2).

Table 2.

Somatic BCL-6 and IgHmutations and expression of BCL-6 protein

IgH somatic mutationsIg coding capacityBCL-6 somatic mutationsBCL-6 protein expression
Patient no.     
 1 NC NC 
 2 NC NC +  
 3 17 − 
 4 24 −  
 5 14 
 6 29 − +  
Cell line     
 L540 NC NC −/+ 
 Holden NC NC 
 L1236 30* + 8/15/8 
 KMH2 26 
 L428 20 2/8 
 L591 26 − 1/0 −/+ 
IgH somatic mutationsIg coding capacityBCL-6 somatic mutationsBCL-6 protein expression
Patient no.     
 1 NC NC 
 2 NC NC +  
 3 17 − 
 4 24 −  
 5 14 
 6 29 − +  
Cell line     
 L540 NC NC −/+ 
 Holden NC NC 
 L1236 30* + 8/15/8 
 KMH2 26 
 L428 20 2/8 
 L591 26 − 1/0 −/+ 

The BCL-6 somatic mutations are in the 5′-noncoding region.

NC indicates not calculable due to absence of Igrearrangements in the presence of rearranged TCR genes; S, single cells; −/+, 5% to 10%; +, 90% to 100%; −, negative.

*

Refers to the functional IgH coding region.

Indicates the number of BCL-6 mutations on the different alleles. Note: L1236 harbor 3 alleles ofbc16.22 

Single base substitution in the IgH promoter region (Octamer binding site).

BCL-6 sequence analysis in single cells and cell lines

For analysis of the 5′-noncoding region of the BCL-6gene, 202 single HRS cells were isolated from 6 cases of cHD. In addition, 172 single CD30 reactive lymphoid cells were extracted from the same tissue specimens to determine irrelevant individual polymorphism. Furthermore, 6 HD-derived cell lines were included in this study. From each cell line, 5-18 sequences were analyzed by cloning of the PCR products. Only base substitutions that were repeatedly found in completely independent analyses were considered as real mutations. Unique alterations were regarded as errors of the Taq polymerase. The BCL-6 sequences of all 4 B-cell–derived HD cases and the 4 B-cell–derived HD cell lines carried 1-15 somatic alterations (Tables3 and 4). Approximately half of these mutations represented transitions, whereas the remaining half represented transversions. The base substitutions observed in the CD30+ HRS cells were not detectable in CD30 reactive cells isolated from the same tissue sections. This clearly indicates that the BCL-6mutations observed in HRS cells are somatic and were most likely introduced in the course of the GC reaction. Most of these mutations are new and are not yet described elsewhere. The remaining 4 mutations were recurrent.5 However, 2 of these mutations were located in a RGWY mutation hotspot,5 and another one occurred at a site that was also reported to be mutated in reactive B cells.5 Therefore, 3 of 4 recurrent mutations do not represent lymphoma-specific base substitutions.

Table 3.

Analysis of the 5′-noncoding regulatory region of theBCL-6 gene in cHD of the T- and B-cell genotype

Patient GenotypeHRS cellsReactive cells
Cells
studied
Mutated/unmutated Nucleotide
changes
Cells studiedIdentical/nonidentical
19 0/5 None NA NA 
30 0/7 None NA NA 
42 3/0 99A>C 25 0/3 
    122G>C3-150   
    448G>C   
50 2/4 202A>C 16 0/23-151 
    284A>G   
    300G>C   
    397G>C   
42 3/1 311A>C 70 0/6 
    518delG   
19 4/1 520delT 61 0/5 
Patient GenotypeHRS cellsReactive cells
Cells
studied
Mutated/unmutated Nucleotide
changes
Cells studiedIdentical/nonidentical
19 0/5 None NA NA 
30 0/7 None NA NA 
42 3/0 99A>C 25 0/3 
    122G>C3-150   
    448G>C   
50 2/4 202A>C 16 0/23-151 
    284A>G   
    300G>C   
    397G>C   
42 3/1 311A>C 70 0/6 
    518delG   
19 4/1 520delT 61 0/5 

Reference sequence corresponds to AF191831.5Identical/nonidentical indicates the identity of the BCL-6mutations observed in reactive cells with those in HRS cells. Mutations reported as recurrent in FL and DLBCL5 are in bold, and the polymorphism at position 397 (397G>C)5 is in italics.

Del indicates deletion; NA, not analyzed.

F3-150

Indicates mutation in a RGWY motif.5 

F3-151

The 2 sequences represent both alleles because only one of the 2 sequences has the polymorphism at position 397 (397G>C).5 

Table 4.

Characteristic changes in the 5′-noncoding regulatory region of the BCL-6 gene in Hodgkin disease cell lines

Cell lineGenotypeNucleotide changes
L5404-150 None 
Holden None  
KMH24-150 (a)  607G>A 
L4284-150 (a)  201T>G, 246T>C 
  (b)  82G>A, 92T>A, 119C>T, 290T>C, 301A>G, 337A>C, 445A>T, 484T>C 
L591 (a)  122G>C4-151 
  (b)  None 
L1236 (a)  123C>G4-151, 220G>C, 299G>A, 390A>C, 435C>T, 437G>A4-153, 506delA, 580C>G 
  (b)  181A>G, 235T>C, 279delT, 314A>T, 327A>G, 328G>T, 377G>C, 427T>A, 445A>C, 498G>C, 510C>T, 518G>A, 541T>A, 543C>G, 569T>G  
  (c)  181A>G, 220G>C, 299G>A, 390A>C, 435C>T, 437G>A4-153, 506delA, 580C>G 
Cell lineGenotypeNucleotide changes
L5404-150 None 
Holden None  
KMH24-150 (a)  607G>A 
L4284-150 (a)  201T>G, 246T>C 
  (b)  82G>A, 92T>A, 119C>T, 290T>C, 301A>G, 337A>C, 445A>T, 484T>C 
L591 (a)  122G>C4-151 
  (b)  None 
L1236 (a)  123C>G4-151, 220G>C, 299G>A, 390A>C, 435C>T, 437G>A4-153, 506delA, 580C>G 
  (b)  181A>G, 235T>C, 279delT, 314A>T, 327A>G, 328G>T, 377G>C, 427T>A, 445A>C, 498G>C, 510C>T, 518G>A, 541T>A, 543C>G, 569T>G  
  (c)  181A>G, 220G>C, 299G>A, 390A>C, 435C>T, 437G>A4-153, 506delA, 580C>G 

Reference sequence corresponds to AF191831.5 If different alleles were detected, they are marked with (a), (b), or (c). Mutations reported as recurrent in FL and DLBCL5 are in bold.

F4-150

The same results have already been described in Carbone et al.13 In addition, mutation 445A>T was found in cell line L428. Furthermore, we were able to discriminate both alleles in this cell line.

F4-151

Mutation is located at an RGWY motif.5 

The presence of 3 alleles in cell line L1236 is in harmony with its karyotype.22 

F4-153

Site of mutation also described in reactive B cells.5 

In contrast to the B-cell–derived cHD cases and cell lines, both cHD cases with T-cell genotype, as well as the 2 T-cell–derived HD cell lines, were unmutated (Tables 3 and 4). To determine whether the 5′-noncoding region of the BCL-6 gene of GC T cells could be affected by the somatic hypermutation machinery, we isolated 29 GC T cells identified by their β-F1 positivity. The sequence analysis of the 5 resulting BCL-6 PCR products disclosed that none of these cells displayed somatic mutations introduced in the GC environment.

Correlation of the somatic IgH andBCL-6 mutations and BCL-6 protein expression

We compared the frequency of somatic mutations found in the 5′-noncoding region of the BCL-6 gene with those published for the IgH genes in corresponding cases (Table2).12 17 Although all cases with IgH mutations displayed BCL-6 mutations, there was no correlation in the number of mutations. Furthermore, there was no correlation between the number of BCL-6 mutations and the BCL-6 expression.

Previous studies have shown a correlation between the appearance of somatic hypermutations in the Ig genes and the presence of mutations in the 5′-noncoding region of the BCL-6gene.1,3-5 Consequently, this correlation can also be observed in B-cell non-Hodgkin lymphoma (NHL), such as FL and DLBCL, which carry high loads of mutations in their Iggenes.3 5 The precise role of BCL-6 in the pathogenesis of the NHL is, however, not yet clear.

CHD represents a lymphoma entity that is derived from B cells with highly mutated Ig genes in most instances (approximately 98%) and from T cells in a few cases (approximately 2%).12 To determine whether B-cell–derived cHD cases, as well as T-cell–derived cHD cases, carry mutations in their 5′-noncoding region of the BCL-6 gene, we isolated 202 single HRS cells from 6 patients with cHD. Four of these patients harbored HRS cells of B-cell genotype, whereas 2 further patients harbored HRS cells of T-cell genotype.12 For comparison, 6 HD cell lines (4 with B-cell genotype and 2 with T-cell genotype) were included in this study, and 201 single reactive cells were analyzed.

The results obtained were equivocal in that all patients with B-cell–derived HD and HD cell lines of B-cell type were found to carry somatic BCL-6 mutations. In contrast, patients with T-cell–derived HD and cell lines were devoid of base substitutions in the BCL-6 gene as well as T cells isolated from the GC. This indicates that reactive GC T cells are not affected by the mutational machinery, whereas this has already been demonstrated for reactive GC B cells in previous investigations.1 2 The finding ofBCL-6 mutations in patients with B-cell–derived HD raises the question of the role these alterations play in the pathogenesis of HD.

For this purpose we analyzed the position of the BCL-6mutations and compared these findings with previously published data described for B-cell NHL5 as well as with theBCL-6 sequences obtained from nonmalignant cells of our own cHD cases. In 3 of 4 B-cell–type HD cases, the detectedBCL-6 mutations represent single base substitutions not previously described or which are located in known mutational hotspots (RGWY motif).5 These alterations can be considered as irrelevant somatic mutations not affecting the expression of theBCL-6 gene. In the remaining case, however, a deletion of thymidine (T) at position 520 (520delT), which is described as the most common recurrent mutation in B-cell NHL, was found.5 This deletion might cause an up-regulation ofBCL-6 gene expression, ie, by the generation of a new transcription factor binding site (eg, MZF1). This assumption is in harmony with the results of the protein expression analysis in this case because a strong expression of BCL-6 was found in virtually all tumor cells. In contrast, in all other B-cell–derived cHD cases, the HRS cells were negative for BCL-6 with the exception of a few scattered tumor cells.

The absence of relevant BCL-6 mutations, as well as the absence of BCL-6 protein expression, in all but one case of the B-cell genotype challenge the role of BCL-6 in the pathogenesis of cHD. Based on previous data it can be assumed that HRS cells represent late GC B cells that were not selected for antigen affinity and carry nonfunctional Ig rearrangements in approximately 30% of cases.17,18 Furthermore it was shown that the absence ofIg expression is not due to crippled Igmutations, but rather to a defective transcription machinery.17 The absence of BCL-6 expression fits well in this scenario because late GC B cells and post-GC B cells are largely BCL-6.19 Thus, the missing BCL-6 expression in most HRS cells can be interpreted as reminiscence of the differentiation stage of the tumor precursor cells.

The complete absence of BCL-6 mutations in T-cell–derived cHD cases clearly indicates that alterations in this gene are not involved in the pathogenesis of this type of HD. The finding that one of the 2 T-cell–derived HD cases showed, despite the absence ofBCL-6 mutations, an expression of BCL-6 could reflect a derivation from BCL-6+ (GC) T cells. Because reactive GC T cells do not carry BCL-6 mutations, they are not affected by the mutational machinery responsible for Ig mutations. This is in contrast to the findings in cHD of B-cell type, where the transformational event seems to be closely related to the activity of the GC mutator.20 21 We conclude from these findings that the molecular events that are responsible for the pathogenesis of B-cell–derived cHD are different from those giving rise to T-cell–derived cHD.

In conclusion, our data show that B-cell–derived cHD cases carry somatic mutations in the 5′-noncoding region of the BCL-6gene, whereas T-cell–derived cHD cases, as well as GC T cells, were unmutated. This supports a 2-entity concept for B- and T-cell–derived cHD. Because only one case carried a lymphoma-specific recurrent mutation and BCL-6 was absent from the HRS cells in most cases,BCL-6 does not appear to be relevant for the pathogenesis of both B-cell– and T-cell–type cHD.

We are indebted to D. Jahnke, H. Lammert, and H. Protz for their excellent technical assistance and L. Udvarhelyi for his editorial help.

Sponsored by a grant (70-2202-Mü3) from Deutsche Krebshilfe, Bonn, Germany, and by a grant (9917155) from Berliner Krebsgesellschaft, Berlin, Germany.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Pasqualucci
L
Migliazza
A
Fracchiolla
N
et al
BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci.
Proc Natl Acad Sci U S A.
95
1998
11816
11821
2
Shen
HM
Peters
A
Baron
B
Zhu
X
Storb
U
Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes.
Science.
280
1998
1750
1752
3
Migliazza
A
Martinotti
S
Chen
W
et al
Frequent somatic hypermutation of the 5′ noncoding region of the BCL-6 gene in B-cell lymphoma.
Proc Natl Acad Sci U S A.
92
1995
12520
12524
4
Szereday
Z
Csernus
B
Nagy
M
Laszlo
T
Warnke
RA
Matolcsy
A
Somatic mutation of the 5′ noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma.
Am J Pathol.
156
2000
1017
1024
5
Lossos
IS
Levy
R
Mutation analysis of the 5′ noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity.
Blood.
95
2000
1400
1405
6
Lo
CF
Ye
BH
Lista
F
et al
Rearrangements of the BCL-6 gene in diffuse large cell non-Hodgkin's lymphoma.
Blood.
83
1994
1757
1759
7
Capello
D
Vitolo
U
Pasqualucci
L
et al
Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia.
Blood.
95
2000
651
659
8
Hummel
M
Ziemann
K
Lammert
H
Pileri
S
Sabattini
E
Stein
H
Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells [see comments].
N Engl J Med.
333
1995
901
906
9
Kuppers
R
Rajewsky
K
Zhao
M
et al
Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development.
Proc Natl Acad Sci U S A.
91
1994
10962
10966
10
Kanzler
H
Hansmann
ML
Kapp
U
et al
Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.
Blood.
87
1996
3429
3436
11
Muschen
M
Rajewsky
K
Brauninger
A
et al
Rare occurrence of classical Hodgkin's disease as a T cell lymphoma.
J Exp Med.
191
2000
387
394
12
Seitz
V
Hummel
M
Marafioti
T
Anagnostopoulos
I
Assaf
C
Stein
H
Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease.
Blood.
95
2000
3020
3024
13
Carbone
A
Gloghini
A
Gaidano
G
et al
Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease.
Blood.
92
1998
2220
2228
14
Cordell
JL
Falini
B
Erber
WN
et al
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).
J Histochem Cytochem.
32
1984
219
229
15
Norton
AJ
Jordan
S
Yeomans
P
Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues.
J Pathol.
173
1994
371
379
16
Marafioti
T
Hummel
M
Anagnostopoulos
I
et al
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells [see comments].
N Engl J Med.
337
1997
453
458
17
Marafioti
T
Hummel
M
Foss
HD
et al
Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.
Blood.
95
2000
1443
1450
18
Kanzler
H
Kuppers
R
Hansmann
ML
Rajewsky
K
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.
J Exp Med.
184
1996
1495
1505
19
Falini
B
Bigerna
B
Pasqualucci
L
et al
Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.
Blood.
87
1996
465
471
20
Marafioti
T
Hummel
M
Anagnostopoulos
I
Foss
HD
Huhn
D
Stein
H
Classical Hodgkin disease and follicular lymphoma originating from the same germinal center B cell.
J Clin Oncol.
17
1999
3804
3809
21
Brauninger
A
Hansmann
ML
Strickler
JG
et al
Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma [see comments].
N Engl J Med.
340
1999
1239
1247
22
Wolf
J
Kapp
U
Bohlen
H
et al
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells.
Blood.
87
1996
3418
3428

Author notes

Harald Stein, Institute of Pathology, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, 12200 Berlin, Germany; e-mail: stein@medizin.fu-berlin.de.

Sign in via your Institution